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Available online 10 November 2017Stem cell therapy is considered a promising approach in the treatment of amyotrophic lateral sclerosis (ALS) and
mesenchymal stem cells (MSCs) seem to be themost effective in ALS animalmodels. The umbilical cord (UC) is a
source of highly proliferating fetalMSCs,more easily collectable than otherMSCs. Recentlywe demonstrated that
human (h) UC-MSCs, double labeled with fluorescent nanoparticles and Hoechst-33258 and transplanted
intracerebroventricularly (ICV) into SOD1G93A transgenic mice, partially migrated into the spinal cord after a
single injection. This prompted us to assess the effect of repeated ICV injections of hUC-MSCs on disease progres-
sion in SOD1G93Amice. Although no transplanted cells migrated to the spinal cord, a partial but significant pro-
tection of motor neurons (MNs) was found in the lumbar spinal cord of hUC-MSCs-treated SOD1G93A mice,
accompanied by a shift from a pro-inflammatory (IL-6, IL-1β) to anti-inflammatory (IL-4, IL-10) and neuropro-
tective (IGF-1) environment in the lumbar spinal cord, probably linked to the activation of p-Akt survival path-
way in both motor neurons and reactive astrocytes. However, this treatment neither prevented the muscle
denervation nor delayed the disease progression of mice, emphasizing the growing evidence that protecting
the motor neuron perikarya is not sufficient to delay the ALS progression.
© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Amyotrophic lateral sclerosis (ALS) is an adult-onset fatal neurode-
generative disorder characterized by the degeneration of motor neurons
in the brain and spinal cord, leading progressively to muscle weakness,
paralysis and finally death for respiratory failure within 3–5 years from
the diagnosis (Cleveland and Rothstein, 2001; Rowland and Shneider,OD1, superoxide dismutase 1;
uman; NP, nanoparticles; ICV,
; NTG, non-transgenic; PBS,
le; GFAP, glial fibrillary acidic
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Neurobiology, Department of
e Mario Negri, Via La Masa, 19,
ndotti).
pen access article under the CC BY-N2001). Almost 90% of ALS cases are sporadic, while 10% are familial, due
to mutations in several genes (Kiernan et al., 2011). Mutation in the
gene coding for SOD1, the first discovered, has led to the development
of animal models of the disease, among which that carrying the
SOD1G93A is the most studied since better reproduce the phenotype of
ALS (Bendotti and Carrì, 2004). Riluzole, which has been approved by
Food and Drug Administration N15 years ago, remains so far the unique
pharmacological treatment showing a modest effect in delaying the sur-
vival of patients by 3–6 months and of about 10 days in mouse models.
This paucity in therapy is likely due to the multifaceted nature of ALS
which involves different pathogenicmechanisms and various non-neuro-
nal cells including glial and immune cells which can play either neurotox-
ic or neuroprotective action depending on their state of activation.
Recently, stem cell therapy has emerged as a promising approach for
several neurological disease treatment, including ALS (Adami et al.,
2014). Not only neural stem cells but also other cell types likemesenchy-
mal stem cells (Lewis and Suzuki, 2014), umbilical cord blood stem cells
(Garbuzova-Davis et al., 2012), glial-restricted progenitor cellsC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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models of ALS. Their mechanism of action is not due to the substitution
of degenerating motor neurons, but rather to the creation of a protective
milieu near the motor neurons through secretion of neuroprotective fac-
tors and the reduction of neuroinflammation (Coatti et al., 2015). The
promising results from preclinical studies prompted several early-phase
clinical trials with hMSCs aimed to establish the safety of the treatment
and delivery method (Glass et al., 2016; Mazzini et al., 2015).
The human umbilical cord (hUC) is a viable source of mesenchymal
stem cells (MSCs), which can be collected easily, in a painless manner
and without ethical concerns because umbilical cord is a discarded tis-
sue (Watson et al., 2015). hUC-MSCs hold a high proliferative rate, are
immunoprivileged thanks to the low expression of MHCI molecules
and the absence of MHCII expression which avoid their rejection
(Todeschi et al., 2015). Moreover, they secrete diverse trophic factors
and cytokines and display strong anti-inflammatory and immunomod-
ulatory capacities (Koh et al., 2008; Lund et al., 2007). For all these rea-
sons, the use of hUC-MSCs could be more advantageous and beneficial
than the MSCs from other sources.
In a previous study, we observed that labeled hUC-MSCs, adminis-
tered by a single intravenous bolus, accumulated in lungs but they mi-
grate neither in the brain nor spinal cord and were rapidly removed
from filter organs in about 24 h (Violatto et al., 2015). On the contrary,
when they were transplanted into cerebral ventricles (ICV), although
most of them remained confined to the site of injection, few were found
in the spinal cord of SOD1G93Amice especially oneweek after transplan-
tation (Violatto et al., 2015). This distribution was similar to that found
after a single ICV injection of humanumbilical cord bloodwhichproduced
amodest amelioration of the disease progression in SOD1G93A andwob-
bler mice suggesting a bystander mechanism through the secretion of
neurotrophic factors (Bigini et al., 2011). Thus, in the present study, to en-
hance the probability of cell migration and the effect of secreted factors in
all the spinal cord segments we decided to perform repeated ICV injec-
tions of hUC-MSCs and to examine their distribution and their effect on
disease progression and neuropathology in SOD1G93A mice. Treatment
with MSCs from bone marrow improved motor performances and
prolonged the survival of transgenic SOD1G93Amicewhen administered
intravenously, starting at the early presymptomatic phase (Zhao et al.,
2007), or at the onset (Uccelli et al., 2012) of disease. In addition human
MSCs act preventively on the disease onset if transplanted into the spinal
cord (Vercelli et al., 2008) or delivered intrathecally (Kim et al., 2010).
Here we decided to start the transplantation when the mice exhibit the
first sign of disease, i.e. the interruption of bodyweight growth compared
to their non-transgenic littermates which occurs around 98 days of age
(Caron et al., 2015) a condition more consistent with the therapeutic ap-
proach in ALS sporadic patients. We injected the hUC-MSCs into lateral
ventricles once every two weeks up to three times in total and we exam-
ined their accumulation and distribution in the CNS using fluorescent
nanoparticles as previously made. In parallel we assessed their effect on
motor neuron degeneration in the lumbar spinal cord, muscle denerva-
tion, disease progression and survival of SOD1G93A mice. We demon-
strated that even after repeated ICV injections, hUC-MSCs remained
confined to the cerebral ventricles and did not migrate into the spinal
cord of mutant SOD1 mice. However, they were able to partially protect
the motor neuron and reduce microglia activation in the lumbar spinal
cord suggesting a bystander action through the secretion of neuroprotec-
tive factors. Nevertheless, this effect was not associated with the preven-
tion of limbmuscle denervation or with a slowing of disease progression.
2. Methods
2.1. Human UC-MSCs cultures
Fresh human UCwere collected from the Operating Room of the Ob-
stetrics and Gynecology Unit at ASST Papa Giovanni XXIII in Bergamo
(Italy). Informedwritten consentwas obtained fromeach donormotheraccording to the guidelines of ethical committee of the ASST Papa
Giovanni XXIII, as required by the clinical trial "Umbilical Cord Derived
Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resis-
tant Graft Versus Host Disease" (ClinicalTrials.gov Identifier:
NCT02032446) approved by “Istituto Superiore di Sanità” and “Agenzia
Italiana del Farmaco”. After cesarean sections, UC-MSCs have been iso-
lated from the whole UC by tissue mechanical disaggregation and culti-
vated, as previously described (Capelli et al., 2015). Briefly, the UC was
cut into 5 cm long segments which were longitudinally cut and split
open to expose the inner surface. Each UC segment, subsequently
minced in very small fragments, was transferred into 150 mm cell cul-
ture Petri dishes (Corning) containing MSC expansion medium
consisting of alpha-MinimumEssentialMedium(MEM) (Life-Technolo-
gies) enrichedwith 5% human platelet lysate obtained from healthy do-
nors, 50 μg/ml gentamicin (Fisiopharma) and 2 UI/ml Heparin
(Hospira). They were maintained at 37 °C in a humidified atmosphere
with 5% CO2 for 6–7 days after which the UC tissue was removed and
the adherent cells were allowed to expand for an additional week.
After approximately 14 days, the adherent cells were harvested by
TrypLe Select 1X (Life-Technologies) treatment and re-plated in T175
flasks (BD Falcon) in MSC expansion medium for further expansion.
Immunophenotype analysis and multilineage differentiation potential
of cells have been extensively characterized (Capelli et al., 2011).
2.2. Nanoparticle synthesis and cell labeling
Poly (methyl methacrylate) nanoparticles (from now on referred to
as NPs) were obtained from a copolymerization between methyl meth-
acrylate (MMA) and a macromonomer of 2-hydroxyethyl methacrylate
covalently bound to Rhodamine b (RhB). This process avoids the disper-
sion of dyes and the consequent risk of biological elution, as previously
described (Dossi et al., 2013). For cell tracking experiment, UC-MSCs
were incubated with 200 nm RhB-positive NPs with a concentration of
1.25 × 1010 NPs/ml for 48 h and Hoechst 33258 (4 μg/ml) for 12 h as
previously described (Bigini et al., 2016; Violatto et al., 2015).
2.3. Animals and treatment
Female adult transgenic SOD1G93A mice on C57BL6/J background
were used in this study as male mice are normally used for breeding
to maintain the colony. All animals were housed under SPF (specific
pathogen free) conditions at a temperature of 22±1 °C, relative humid-
ity of 55± 10% and 12 h light/dark schedule, 5 per cage. Food (standard
pellets) (Altromin, MT, Rieper) and water were supplied ad libitum.
Procedure involving animals and their care were conducted in accord-
ing to the institutional guidelines, that are in compliance with national
(D.lgs 26/2014; Authorization n.19/2008-A issued March 6, 2008 by
Ministry of Health) and international laws and policies (EEC Council Di-
rective 2010/63/UE; NIH Guide for the Care and use of Laboratory Ani-
mals, U.S. National Research Council, 2011 edition). This specific
protocol was approved by IRCCS-IRFMN Animal Care and Use Commit-
tee (IACUC) and then approved by the Italian “Istituto Superiore di
Sanità” (code: No 1131/2015 PR).
Mice SOD1G93A (n=58) of 98 days of age were randomly assigned
to different experimental groups, so that the mean body weight was
similar between groups. For histological, biochemical and behavioral
analyses 46 SOD1G93Amicewere recruited,while for ex vivo cell track-
ing analysis 12 SOD1G93A mice were used. Non-transgenic age
matched mice (NTG) (n=13) were recruited as control for both histo-
logical and biochemical analysis. The experimental schedule is reported
in Table 1.
The 46 SOD1G93Amice enrolled for the evaluation of hUC-MCSs ef-
fectiveness were further divided into two groups: the first (n= 23) re-
ceiving 250,000 hUC-MSCs resuspended in 8 μl of sterile PBS into the
lateral cerebral ventricles, the second (n= 23) receiving the same vol-
ume of sterile PBS (vehicle). The experimental group composed of 12
Table 1
Experimental groups for in vivo analyses. L = labelled; d= days of age; d = day; X = sacrifice.
14 w 14 w + 1 d 16 w 18 w 20 w End stage
SOD1G93A UC-MSCs n= 8 ICV ICV ICV X Biochemistry histology
SOD1G93A PBS n= 8 ICV ICV ICV X
SOD1G93A UC-MSCs n= 15 ICV ICV ICV ICV X Behavior
SOD1G93A PBS n= 15 ICV ICV ICV ICV X
SOD1G93A L UC-MSCs n= 3 ICV X Cell tracking
SOD1G93A L UC-MSCs n= 3 ICV X
SOD1G93A L UC-MSCs n= 3 ICV ICV X
SOD1G93A L UC-MSCs n= 3 ICV ICV ICV X
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beled hUC-MSCs.
To avoid an excessive load in a single ventricle, 4 μl were injected for
each side. Animals received an intraperitoneal (ip) injection of the anal-
gesic Buprenorphine (100mg/kg) dissolved in sterile saline solution be-
fore the surgical procedure. They were anesthetized with a 5%
isoflurane/oxygen mixture. The following stereotaxic coordinates
were used (anterior-posterior 0.0 mm from the bregma; lateral
±1.0 mm from the bregma; deepness−3.0 mm from skull surface).
For histological and biochemical analyses, 16mice (PBS n=8; hUC-
MSCs n=8) received 3 ICV injections, once every 14 days (98, 112 and
126 days of age) and then sacrificed at 140 days of age, when usually
SOD1G93Amice show about 50% reduction in their motor performance
on Rota-Rod (symptomatic stage).
For the behavioral tests, 30mice (PBS n=15; hUC-MSCs n=15) re-
ceived 4 ICV injections once every 14 days (98, 112, 126and 140 days of
age) and were euthanized at the end stage of the disease considered
when the mice were unable to right themselves within 10 s after
being placed on their sides. The 12 SOD1G93A mice enrolled for cell
tracking study were divided into the following four subgroups: 1) n
= 3 mice were sacrificed 24 h after the first ICV injection; 2) n = 3
mice were sacrificed 6 weeks after the first ICV injection (140 days of
age); 3) n=3mice were sacrificed 2 weeks after the second ICV injec-
tion (126 days of age); 4) n= 3mice sacrificed 2 weeks after the third
ICV injection (140 days of age). ICV injections were performed with a
gap of 2 weeks between each other. At the end of the study, brain and
spinal cord were immediately collected and frozen in liquid nitrogen,
to ensure optimal quality of tissues. Sections (30 μm) were obtained
after cryostat cutting and observed with a BX81 microscope equipped
with an F-view II CDD camera (Olympus).
2.4. Disease progression assessment
The disease progressionwas evaluated in allmice (PBS n=15; hUC-
MSCs n=15), twice a week from the start of the experiment, by an op-
erator blinded to the treatment. The parameters measured included
body weight, latency to fall from the Rota-Rod and from the grid (grip
strength) as previously described (Tortarolo et al., 2015). Body weight
was monitored before behavioral tests and immediately before and
after the surgery and aswell as the day after to ensure that themice tol-
erated the procedure without major surgical complications, such as in-
jection-attributable neurological worsening. The Rota-Rod test was
performed using the Rota-Rod apparatus (model 7650, Ugo Basile).
The animals were placed on the rotating bar with a constant accelera-
tion of 4 rotations per minute (rpm) starting from a speed of 7 rpm up
to 28 rpm for a maximum of 300 s. The latency to fall was recorded
and the test was repeated for a maximum of three times interspersed
by 5 min rest between sessions. For the grip strength test to measure
the limb resistance, mice were placed on a horizontal metallic grid
that was slightly shaken to force the mouse grip and then inverted.
The latency to fall of each mouse was recorded. The test ended after
90 s; in the case of failure, the measurement was repeated three
times. The best performance of the sessions was considered for the sta-
tistical analysis.2.5. Histological examination
For histological analyses, 12mice (NTG n=4; PBS n=4; hUC-MSCs
n=4) at the symptomatic stage of the disease and 15mice (NTG n=5;
PBS n=5; hUC-MSCs n=5) at the end stagewere deeply anesthetized
with ketamine hydrochloride (150 mg/kg) and medetomidine
(2 mg/kg) followed by intracardiac perfusion with 4% paraformalde-
hyde (PFA, Merck) in PBS 0.1 M, pH 7.4. Spinal cords were removed
and post-fixed for 24 h in 4% PFA in PBS 0.1 M (Tortarolo et al., 2015).
Tissues were dehydrated in 30% sucrose solution in PBS until they
sank, embedded in cryostat medium OCT (Sakura, Zoeterwounde, The
Netherlands) and then frozen in N-pentane at −45 °C for 3 min and
conserved at−80 °C. Thirtymicrometre coronal sectionswere obtained
by cutting lumbar spinal cords (L2–L5) using a cryostat at−20 °C. The
spinal cord sections were collected in PBS 0.01 M and transferred in a
cryo-preservative solution (NaH2PO4, Na2HPO4, MilliQ H2O, Ethylene
Glycol, Glycerol) and stored at−20 °C until use. For the evaluation of
the NMJ denervation according to the previously described protocol
(Tortarolo et al., 2015), tibialis anterior muscles (TAM) were dissected
and snap-frozen in cooled isopentane. Sagittal sections (20 μm) were
obtained using a cryostat at −20 °C; they were then placed on a
polylisinate glass and stored at−20 °C until use.
2.5.1. Nissl staining and motor neuron counts
For motor neuron counting, 20 serial coronal sections (1 every 10)
from lumbar spinal cord per animalwereNissl-stained as previously de-
scribed (Peviani et al., 2014). Motor neuron counting was performed at
10× magnification using the free software ImageJ (http://imagej.nih.
gov/ij/), previously calibrated. Only the large polygonal neurons with
a cell body area ≥ 400 μm2,with a clear nucleolus and a distinctly labeled
Nissl-dense cytoplasm, located in a congruent positionwere incorporat-
ed into the counts. The number of motor neurons was calculated for
each hemisection and the means used for statistical analysis.
2.5.2. Immunofluorescence of lumbar spinal cord
Immunofluorescence was evaluated on 6 coronal spinal cord slides
(1 every 10) from lumbar spinal cord per animal. After blocking the
non-specific binding sites by incubationwith a solution containing nor-
mal goat serum (NGS 10%) and Triton (0.3%) in PBS 0.01M, the sections
were incubatedwith the primary antibodies (overnight at 4 °C), diluted
in a solution containing NGS and Triton in PBS 0.01M:mousemonoclo-
nal anti-GFAP (1:2500, MerkMillipore), rabbit anti-IBA1 (1:500,Wako)
mouse anti-SMI-31 (1:1000, Sternberger Inc.). After three washes in
PBS 0.01 M, the sections were incubated (1 h at room temperature)
with appropriate secondary antibodies conjugated with a fluorophore
(Alexa Fluor® Dyes, Life Technologies), diluted (1:500) in a solution
containing NGS (1%) in PBS 0.01 M: Alexa 488 anti-mouse, Alexa 488
anti-rat and Alexa 647 anti-rabbit. Then after 3 washes in PBS 0.01 M,
the sectionsweremounted on glass slides and then coveredwith cover-
slips using FluorSaveTM (Calbiochem). The quantification of GFAP and
IBA1 intensity was carried out by the same operator blinded to treat-
ment, by determining the mean gray value of fluorescent signals in
the ventral horns in the relative surface occupied by the staining. The
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immunostaining and 40× magnification for SMI-31 immunostaining,
using the free software ImageJ (http://imagej.nih.gov/ij/). Immunofluo-
rescence for SMI-31 was performed with same protocol used for GFAP
and IBA1 using as primary antibody mouse anti-SMI-31 (1:1000,
Sternberger Inc.).
2.5.3. Immunohistochemistry of p-Akt
Endogenous peroxidases were inactivated by 1% hydrogen peroxide
in TBS (0.1M Tris–HCl, 0.14 MNaCl, pH 7.4). The sections were then in-
cubated with 3% bovine serum albumin (BSA) in TBS/Triton 0.1% 1 h at
RT, and then probed overnight at 4 °C in 3% BSA, TBS/Tritonwith an anti-
p-Akt rabbit polyclonal antibody, 1:500 dilution, from Cell Signaling.
Subsequently, the sections were washed in TBS/Triton and incubated
1 h at RT in 1% BSA, TBS with a secondary biotinylated anti-rabbit anti-
body, 1:200 dilution, fromVector. The secondary antibodywas revealed
with a TSA amplification kit, Cy5 (Perkin Elmer) as previously described
(Peviani et al., 2007).
For each immunofluorescence procedure, some of the sections were
processed without primary antibody, to verify the specificity of the
staining.
2.5.4. Neuromuscular junctions (NMJs)
Detection of the NMJ denervation wasmade in five non consecutive
sagittal sections of TAM. Slices were fixed in acetone for 10 min, incu-
bated in a blocking solution (0.3% Triton, 10% NGS in 0.01 M PBS) for
1 h at 22 °C and then left overnight at 4 °C with anti-synaptophysin pri-
mary antibody (rabbit, 1:100, Synaptic System) in 0.15% Triton, 5% NGS,
0.01 M PBS. The sections were then incubated with goat anti-rabbit 647
(1:500, Alexa Fluor® Dyes, Life Technologies) secondary antibody and
with bungarotoxin (1:500, Invitrogen) conjugated with Alexa Fluor®
594 (Life Technologies). Dual-staining co-localization of pre and post-
synapticmarkerswas analyzed at 20×magnification under anOlympus
Fluoview confocal microscope (FV1000). Innervated neuromuscular
junctions were identified by totally or partially co-localization of
synaptophysin with bungarotoxin. Plaques marked with bungarotoxin
only were considered denervated and they were expressed as the per-
centage of the total plaques (counted in 8 adjacent frames per section).
2.6. Western blot
The lumbar spinal cord (NTG = 4; PBS = 4; hUC-MSCs = 4) was
rapidly dissected and processed as previously described (Tortarolo et
al., 2015). The tissue was homogenized by sonication in ice-cold ho-
mogenization buffer (20 mM Tris-HCl pH 7.4, 2% Triton X-100 1%,
150 mM NaCl, 1 mM EDTA, 5 mMMgCl2, anhydrous glycerol 10%, pro-
tease and phosphates inhibitor cocktail, Roche), centrifuged at
13,000 rpm for 30min at 4 °C. Proteins from supernatant were separat-
ed by electrophoresis on polyacrylamide gels and transferred onto
polyvinylidene difluoride (PVDF) membranes. Blots were probed with
primary antibodies, mouse monoclonal anti-GFAP (1:1000, Millipore),
rabbit polyclonal anti-IBA1 (1:1000, Wako); rabbit monoclonal anti-p-
Akt (1:750, Cell Signaling); anti-Akt, (1:1000, Cell Signaling); mouse
monoclonal anti-GAPDH (1:20,000, Millipore), and then with peroxi-
dase-conjugated appropriate secondary antibodies. Blots were devel-
oped with Immobilon Western Chemiluminescent HRP Substrate
(Millipore) on the Chemi-Doc XRS System (Bio-Rad Laboratories, Her-
cules, CA, USA).
2.7. Real-time PCR
Spinal cords were freshly collected and frozen on dry-ice. Total RNA
from spinal cord was extracted using the Trizol method (Invitrogen)
and purifiedwith PureLink RNA columns (Life Technologies). RNA sam-
pleswere treatedwithDNase I and reverse transcriptionwas performed
with High Capacity cDNA Reverse Transcription Kit (Life Technologies).Real-time PCRwas performed using the TaqManGene expression assay
(Applied Biosystems) following the manufacturer's instructions, on
cDNA specimens in triplicate, using 1× Universal PCR master mix (Life
technologies) and 1× mix containing specific receptors probes for the
interleukin 1 beta (IL-1β, Mm00434228_m1); interleukin 4 (IL-4,
Mm00445259_m1); interleukin 6 (IL-6, Mm00446190_m1); interleu-
kin 10 (IL-10, Mm00439614_m1); insulin growth factor1 (IGF-1,
Mn00439560_m1). Relative quantification was calculated from the
ratio between the cycle number (Ct) at which the signal crossed a
threshold set within the logarithmic phase of the given gene and that
of the reference β-actin gene (4310881E; Life Technologies). Mean
values of the triplicate results for each animal were used as individual
data for 2-ΔΔCt statistical analysis.
2.8. Statistical analysis
Statistical analyseswere performed using the Prism software (Graph
Pad Prism 6, Graph Pad Inc.), USA. Body weight, Rota-Rod test, grip
strength test data were analyzed using ANOVA for repeated measures,
followed by Tukey's Post Hoc test. Survival analysis was performed by
the Log-rank test. For the histological analyses, the data were statistical-
ly analyzed using One way ANOVA followed by Tukey's Post Hoc test.
3. Results
3.1. hUC-MSC clusters in the ventricle but do no migrate to spinal cord
parenchyma
A representative pattern of hUC-MSC distribution at different time
points in the brain of SOD1G93Amice is reported in Fig. 1. In accordance
with our previouswork (Violatto et al., 2015), clusters of double-labeled
hUC-MSCswere largely detected at the level of lateral ventricles strong-
ly associated with the choroid plexus cells (Fig. 1A-B). Six weeks after
one single treatment, the size and the number of events forming these
cell clusters markedly decreased into lateral ventricles. Interestingly, a
signal related to cells was found along more caudal ventricle structures
below hippocampus region (Fig. 1C-D).
In order to enhance the accumulation and the therapeutic efficacy of
stem cells,multiple treatmentswere carried out. A comparison between
double and triple cell administration is shown in Fig. 1E-F-G-H. In both
conditions, UC-MSCs are still located along ventricle structures. An in-
crease of cell clusters was observed close to the site of injection and
near hippocampus area compared to animals receiving a single admin-
istration (Fig. 1C-D). Cell tracking also revealed that, despite the multi-
ple administrations, hUC-MSCs did not migrate in the brain
parenchyma, even close to the ventricles (Fig. 1), and in the spinal
cord (not shown).
3.2. hUC-MSC partially prevent the motor neurons loss but not the muscle
denervation
Motor neuron (MN) count performed on lumbar spinal cord sections
from 140-day-old SOD1G93Amice injected with PBS showed a marked
reduction of alpha-motor neuron (≥400 μm2) compared to non-trans-
genic littermates and this effect was significantly attenuated in hUC-
MSCs-treated SOD1G93A mice (NTG, 17.66 ± 1.20; hUC-MSCs, 10.25
± 0.60 vs PBS, 7.28± 0.29, p b 0.05) (Fig. 2D). In addition, also the func-
tionality of motor neuron was ameliorated in 140-day-old SOD1G93A
mice treated with hUC-MSCs (Fig. 2E-G). In fact, while in NTG mice
(Fig. 2E) the phosphorylated neurofilaments, labeled with SMI-31,
were present in neuropil, axon terminals, and dendrites, leaving the
perikarya totally unstained in symptomatic SOD1G93A mice, SMI-31
immunofluorescence accumulates in altered neuronal structures, such
as vacuolized and dystrophic axons, dendrites and soma, as marker of
MN dysfunction (Tortarolo et al., 2003) (Fig. 2F). These aberrant struc-
tures were less evident in SOD1G93A mice treated with hUC-MSCs
Fig. 1.Double labeled UC-MSCs tracking. Histological brain sections from SOD1G93Amice
sacrificed 24h after thefirst ICV injection (A-B); 6weeks after thefirst ICV injection (C-D);
2 weeks after the second ICV injection (E-F) and 2 weeks after the third ICV injection (G-
H). The blue signal is related to the stainingof stemcell nucleiwith theHoechst-33258 and
the red staining is associated with RhB fluorescent NPs.
170 F. Sironi et al. / Stem Cell Research 25 (2017) 166–178(Fig. 2G) confirming the partial preservation of MN cell bodies in the
spinal cord.
However, when we analyzed the extent of NMJ denervation of the
tibialis anterior muscle of SOD1G93A mice treated with PBS or hUC-
MSCs at symptomatic stage (140 days of age) we found no difference
in the robust plaque denervation observed when compared to NTG
mice (Fig. 3D).
3.3. hUC-MSC reduce the activated microglia but increase the reactive as-
trocytes in the lumbar spinal cord
It has been suggested that stem cells act as support for dying motor
neurons not only by releasing neurotrophic factors but also reducing
neuroinflammation in damaged regions. Therefore we evaluated both
reactive astrocytosis and microgliosis at the symptomatic stage of the
disease, in the lumbar spinal cord of hUC-MSCs treated SOD1G93A
mice compared to those treated with PBS. As expected the immuno-
staining for GFAP, the specific marker of astrocytes was increased in
the spinal cord of SOD1G93A mice treated with PBS compared with
non-transgenic littermates. Unexpectedly, this effect was significantly
exacerbated in hUC-MSCs treated mice (p b 0.05), as demonstrated by
both immunohistochemistry (Fig. 4A-D) and western blot analysis
(Fig. 4E-F). On the contrary, the IBA1 immunostaining, a marker of mi-
croglia activation, was significantly reduced in hUC-MSCs treated
SOD1G93A mice compared to mice treated with PBS at 140 days age(p b 0.001) (Fig. 5A-D). This effect was partially confirmed by the west-
ern blot of lumbar spinal cord homogenate (Fig. 5G-F). In fact, the in-
creased levels of Iba1 in SOD1G93A mice compared to NTG were
reduced by the treatment with hUC-MSCs although the effect did not
reach the statistical significance.
3.4. hUC-MSCs increase the anti-inflammatory cytokine and IGF-1while re-
ducing the proinflammatory cytokines.
As MSCs has been reported to exert their neuroprotective effect by
modulating the inflammatory environment around MNs (Boido et al.,
2014)we examined themRNA levels by real time PCR of pro-inflamma-
tory cytokine (IL-6 and IL-1β) and the anti-inflammatory cytokine (IL-4
and IL-10) in the lumbar spinal cord of hUC-MSCs treated as compared
to PBS treated SOD1G93A mice and non transgenic mice. While the
levels of IL-6 mRNA show a non significant reduction in SOD1G93A
mice treated with PBS with respect to NTG, the levels in hUC-MSCs
treated mice were further reduced and significantly different from the
NGT mice. The mRNA levels of proinflammatory IL-1β, on the contrary,
were increased by about 3 fold in SOD1G93A mice compared to NTG
mice while the hUC-MSCs attenuated this effect (Fig. 6B). Much differ-
ent is the situation for the levels of the anti-inflammatory cytokine IL-
4 mRNA, that did not change in SOD1G93A mice treated with PBS but
significantly increased of about 8-fold compared to NTG and vehicle-
treated transgenicmice (Fig. 6C). Finally, IL-10mRNAwhich significant-
ly decreased in SOD1G93A mice treated with PBS compared to NTG
mice, showed a mild recovery in the hUC-MSCs treated mice even if
not statistically significant (Fig. 6D). Since MSCs were also reported to
induce the production of endogenous neuroprotective factors in the
host transplanted tissue, we examined the levels of IGF-1 which is
known to be a potent survival factor for motor neurons. In line with
this, we found a 4-fold increase in mRNA levels of IGF-1 in the spinal
cord of SOD1G93A treated with hUC-MSCs compared to mice treated
with PBS (Fig. 6E).
3.5. Activation of pro survival pathway in lumbar spinal cord.
In the nervous system activation of the PI3K/Akt pathway is one of
the mechanisms specifically involved in neuronal survival and cell pro-
liferation in response to growth factors and cytokine stimulation
(Brunet et al., 2001; Peviani et al., 2007). For this reason we wanted to
verify if the partial MN protection and the increased astrocytosis ob-
served in the 140-day-old hUC-MSCs treated mice could be linked to
the activation of this pathway. According to previous observation
(Peviani et al., 2007), no changes in the p-Akt/Akt pathwaywere detect-
ed at the symptomatic stage of thedisease betweenNTGand SOD1G93A
treatedwith PBS byWestern Blot, while the p-Akt/Akt ratio significantly
improved in the hUC-MSCs-treated group compared to the vehicle and
NTG (PBS vs. hUC-MSCs p b 0.01) (Fig.7A-B).We also examined the dis-
tribution of p-Akt by immunofluorescence in combinationwith GFAP to
determine the cellular distribution of the activated protein and to define
whether an increase of astrocytosis could be linked to the activation of
this prosurvival pathway. While, in the lumbar spinal cord of NTG
mice p-Akt and GFAP did not colocalized, in SOD1G93A mice we ob-
served a partial co-localization of GFAPwith p-Aktwhichwasmagnified
in the lumbar spinal cord sections from hUC-MSC treated mice.
3.6. hUC-MSC do not alter the disease onset, duration and survival amelio-
rate the disease progression
The trend of body weight change in SOD1G93Amice showed no sig-
nificant differences between the groups treated with PBS or UC-MSCs
(Fig. 8A) indicating a good tolerability of surgical delivery of stem cells
and ruling out possible cell toxicity. We can also exclude any behavioral
deterioration due to the ICV treatment since the variation of body
weight and the grip endurance trend was similar to that reported
Fig. 2.Motor neuron loss and dysfunction. Motor neurons were counted on Nissl stained lumbar spinal cord hemisections from mice at 140 days of age (A-C), scale bar 100 μm. At the
symptomatic stage of the disease motor neurons, with cell body area ≥ 400 μm2 (arrow, A), resulted significantly decreased in both transgenic group of mice compared to non-
transgenic (NTG). Treatment with hUC-MSCs showed a partial but significant neuroprotection (D). The bar graph represents mean ± SEM (n= 4 animals); * = p b 0.0001 vs NTG; §
= p b 0.05 vs SOD1G93APBS (One way ANOVA, followed by post-hoc Tukey's test). In lumbar spinal cord of transgenic mice (F), we observed a marked increase of phosphorylated
neurofilaments (SMI-31 green, arrow) compared to NTG mice (E), as an index of MNs dysfunction. Treatment with hUC-MSCs reduced the accumulation SMI-31 in the motor neuron
cell body labeled with neurotrace (NT, red) and proximal axons (scale bar: 20 μm).
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al., 2003). Compared with the PBS-treated mice, those treated with
hUC-MSCs did not present a better performance on neuromuscular
tests, except for a slight, not significant improvement on both Rota-
Rod test and grip strength at about 126 days of age, the time point at
which the largest number of cellswas detected in the cerebral ventricles
(Fig. 8B-C). The repeated treatment with hUC-MSCs did not prolonged
mice survival (mean: PBS, 170.6 ± 3.3; hUC-MSCs, 174.6 ± 2.5 days).
However, when 50% of PBS-treated mice have died, still 75% of the
hUC-MSCs treatedmicewere alive (Fig. 8D) showing a trend to increase
life span. We can exclude any behavioral deterioration due to the ICVtreatment since the variation of body weight and the grip endurance
trendwas similar to that reported previously from our group in untreat-
ed SOD1G93A mice (Tortarolo et al., 2015).
4. Discussion
MSCs have been considered as a promising tool for the treatment of
ALS as they have multipotential features such as the ability to secrete
neurotrophic factors and exert an immunomodulatory effect. Different
studies have demonstrated the efficacy of MSCs, mostly originating
from the bone marrow or adipose tissue, in delaying the onset of the
Fig. 3.Neuromuscular junction denervation. Neuromuscular junction denervationwas evaluated by immunohistochemistry in tibialis anteriormuscles at symptomatic stage of the disease
(140 days). Representative images of co-localization of synaptophysin (SYN, green) with bungarotoxin (BTX, red) of NTG (A), SOD1G93A PBS (B) and transgenic mice treated with hUC-
MSCs (C) scale bar 50 μm. Percentage of neuromuscular junction denervation was higher in tibialis anterior of SOD1G93A mice respect to NTG, without any difference after the
treatment with hUC-MSCs (D). Data are expressed as mean ± SEM, (n = 4 animals). Statistical analysis was performed using One way ANOVA, followed by post-hoc Tukey's test (p
value b 0.05 vs NTG).
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certain variability in relation to the dose and route of administration
(Lewis and Suzuki, 2014; Zhijuan Mao and Chen, 2015). In this study,
hUC-MSCs were selected for their lower risk of rejection compared to
other stem cells, therefore UC results a more appealing cell source for
application in an allogeneic system. We decided to evaluate the effect
of repeated administration of hUC-MSCs since our previous results
(Violatto et al., 2015) showed that after a single ICV injection the num-
ber of cells that remained longer in the ventricles was limited and only
very few cellsmigrated into the spinal cord oneweek after the injection.
In line with this, here we observed that the size and the number of cell
clusters confined to the third ventricle were markedly decreased
6 weeks after a single injection and no cells were detected in the spinal
cord. Instead, after the second and third administration the size and the
number of cell clusters appeared higher in the ventricles, nevertheless
the presence of cells in the brain or spinal cord parenchymawas not de-
tected. This suggests that the hUC-MSCs have low capacity of migration
and engraftment, therefore their beneficial effect in protecting the
motor neurons and reduce microgliosis in the lumbar spinal cord can
only be associated with a paracrine effect. Such phenomenon has been
suggested also for the neuroprotective effect induced by MSCs from
other sources and delivered intrathecally (Boido et al., 2014; Habisch
et al., 2007; Vercelli et al., 2008).
Several pieces of evidence suggest that MSCs may exert a protective
role on motor neurons in SOD1G93Amice modifying the inflammatory
milieu of the host spinal cord (Boido et al., 2014). In agreement with
this, we found that while the transcription of endogenous murine pro-
inflammatory cytokines, IL-6 and IL-1β, was partially decreased, the
mRNA levels of anti-inflammatory cytokines such as IL-4, and at a
lower level IL-10, were higher in the spinal cord of mice treated with
hUC-MSCs compared to the PBS-treated SOD1G93A mice. These results
indicate a clear shift towards an anti-inflammatory environment. This is
consistent with the attenuation of the activated microglia and aprobable shift from a classically activated M1 phenotype toward an al-
ternative activated or deactivated M2 phenotype with neuroprotective
function, as previously suggested from in vitro and in vivo model of
ALS (Henkel et al., 2009; Zhao et al., 2010). In fact, it has been proposed
that while IL-10may induce anM2 deactivated polarization state of mi-
croglia, IL-4 generates an M2-alternatively activated polarized pheno-
type. M2 microglia in turn may block the release of pro-inflammatory
cytokines and secrete high levels of IL-4, IL-10, and IGF-1, all of which
may enhance neuronal survival (Henkel et al., 2009). Interestingly, in
addition to IL-4, we also found a marked upregulation of IGF-1 in the
spinal cord of hUC-MSCs-treated mice with respect to the vehicle
group. IGF-1 administered through viral delivery either intramuscular
(Kaspar, 2003) or intraparenchymal (Lepore et al., 2007) or by intrathe-
cal administration (Nagano et al., 2005) has been reported to have a
neuroprotective effect in ALS mouse models and this effect was associ-
ated with increased levels of p-Akt in the spinal cord homogenate
(Kaspar, 2003; Nagano et al., 2005). Consistently, here we found that
treatment with hUC-MSCs increased the levels of p-Akt in the spinal
cord homogenate providing a further evidence for the neuroprotective
efficacy in SOD1G93A mice. Moreover, for the first time, we demon-
strate that treatment with hUC-MSCs activated the p-Akt pathway not
only in theMNs but above all, in the reactive astrocytes, which promote
neuron survival. This is consistent with the increase of GFAP immunore-
activity in the lumbar spinal cord of SOD1G93Amice treated with hUC-
MSCs. This effect is probably mediated by the augmented transcription
of IGF-1. In fact, studies in vitro have demonstrated that IGF-1 is a potent
activator of p-Akt inmutant SOD1MN-astrocytes coculture and this is a
key mechanism for IGF-1 to induce neuroprotection against oxidative
stress injury (Dávila et al., 2016). Thus, it is possible that even in the
presence of the pro-oxidant SOD1G93A, the activated astrocytes in the
spinal cord of hUC-MSC treated mice may acquire a neuroprotective
function through the activation of the IGF-1-p-Akt pathway (Dávila et
al., 2016).
Fig. 4. Evaluation of reactive astrocytosis. Representative images of ventral lumbar spinal cord hemisections stained with GFAP (green) at 140 days of age (A-C) scale bar 50 μm.
Quantification of immunofluorescence showed elevated astrocytosis in the ventral horn of SOD1G93A mice at the symptomatic stage of the pathology as compared to NTG. Treatment
with hUC-MSCs significantly increases the reactive astrocytosis (D). Bar graph are mean ± SEM as a percentage versus NTG controls (n = 4–5 animals for each group). Statistical
analysis was performed using One Way ANOVA followed by post hoc Tukey test; * = p b 0.0001 vs NTG; § = p b 0.0001 vs SOD1G93APBS. Representative GFAP immunoblots
performed on the lumbar spinal cord of NTG and transgenic mice treated with PBS or hUC-MSCs, at 140 days of age (E), and relative quantification (F). Bar represents mean ± SEM as
a percentage versus NTG controls (n = 4 animals per group). Data were analyzed using One way ANOVA followed by post hoc Tukey test; * = p b 0.001 vs NTG; § = p b 0.05 vs
SOD1G93APBS
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ipose tissue in SOD1G93Amice reported increased levels of IGF-1 in the
spinal cord in addition to other neurotrophic factors (BDNF, GDNF,
CNTF) (Kim et al., 2014). Interestingly, Jeon and colleagues (Jeon et al.,
2016) using the cytosolic extract of human adipose stem cells (hASC)
demonstrated a significant neuroprotective effect on MN, that is associ-
ated with an increased expression of p-Akt, p-CREB, and PGC-1α in
SOD1G93A mouse model. Thus, together with this observation, our
data suggest that the activation of p-Akt induced by IGF-1 in both
motor neurons and astrocytes play an important role in the neuropro-
tective action of MSCs secretome.
Of note, in the present study, the reduced loss of motor neurons is
not associated with a preservation of the innervated neuromuscular
junction with the consequence of a lack of beneficial effect on the pro-
gression of the disease in SOD1G93Amice. Other studies have reported
similar results in these mice either with cell therapy or other interven-
tions. For example, transplantation of Sertoli cells into the parenchyma
of the lumbar spinal cord significantly protects motor neurons inSOD1G93A mice without modifying the disease onset neither the sur-
vival (Hemendinger et al., 2005). Likewise, treatment with sodium
valproate, which did exert a neuroprotective effect in SOD1G86R mice,
was unable to extend the mean survival of ALS mice, because it did
not ameliorate skeletal muscle denervation (Rouaux et al., 2007). An-
other example refers to the intraparenchymal spinal cord delivery of
adeno-associated virus IGF-1 (Lepore et al., 2007). In fact, while the
treatment with AAV2-IGF-1 delayed the disease onset and extended
survival in male SOD1G93Amice, this effect was not detected in female
SOD1G93A despite a similar protection of spinal motor neurons. This
observation was confirmed by another group who delivered the same
AVV2-IGF-1 in the rat SOD1G93A (Franz et al., 2009). They observed a
significant protection of motor neurons after intraspinal cord delivery
of IGF-1, however only in males there was a partial amelioration of
the grip strength, which was not sufficient to delay the onset and to in-
crease the duration of the disease in both male and female rats. Note-
worthy, another group using human hUC-MSC injected directly into
the lumbar spinal cord of male and female SOD1G93A mice also
Fig. 5. Evaluation of reactive microgliosis. Representative images of ventral lumbar spinal cord hemisections stained with IBA1 (red) at 140 days of age (A–C) scale bar 50 μm. IBA1
immunofluorescence was decreased in mice treated with MSC compared to vehicle group at 140 days of age. Bar graphs are mean ± SEM as a percentage versus NTG controls (n= 4–
5 animals for each group). Statistical analysis was performed using One Way ANOVA followed by post hoc Tukey test; * = p b 0.0001 vs NTG; § = p b 0.0001 vs SOD1G93APBS.
Representative IBA1 immunoblots performed on the lumbar spinal cord at 140 days of age (E), and relative quantification (F). Bar represents mean ± SEM (n= 4 animals per group).
Data were analyzed using One way ANOVA followed by post hoc Tukey test; * = p b 0.05 vs NTG.
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genders with a significant improvement of Rota-Rod and PaGE perfor-
mance only in male mice (Vercelli et al., 2008). Since in the present
study we used only female SOD1G93A mice this may have prevented
us from observing a beneficial effect on the disease progression, even
in presence of a significant neuroprotection. The mechanism for which
the effect is restricted to male is unknown, but the authors suggested
that the differences in disease progression, sex hormones and/or levels
and sensitivity of components of the IGF-1 system may be the cause of
this discrepancy (Lepore et al., 2007). However, this hypothesis de-
serves further investigation.
On the contrary, Zhang et al. (2009) which didmultiple deliveries of
BM-MSC confined to the cerebral ventricles only in female SOD1G93A
mice, showed a beneficial effect on the disease progression in associa-
tion to MNs protection. They began their first treatment at the early
pre-symptomatic stage (8weeks of age) and this may be relevant to
the protection of the NMJs, since it has been suggested that alterations
in distal motor axons are the earliest pathological changes in the patho-
genesis of ALS, followed by a “dying back” process (Fischer et al., 2004).
Thus, in the Zhang's study the growth factors produced and secreted by
cells in the CSF may have more time to reach the peripheral nervoussystem and to improve the function of the NMJs. In addition, in Zhang's
study the number of cells injected was double than those administered
in our study and, importantly, the survival rate of hUC-MSCs in CSF
seems to be lower than that of BM-MSCs (Habisch et al., 2007). This sug-
gests that transplanting stem cells in peripherymight havemore impact
on the disease progression in SOD1G93A mice. In fact, there are several
studies showing delay in disease progression and increased survival of
SOD1G93A mice after intravenous injection of MSCs from different
sources (Kim et al., 2014; Sun et al., 2014; Zhao et al., 2007). A
disadvantage of the peripheral administration is that it requires a
huge amount of cells to be injected and since most of them end up
in the lungs and the liver to be expelled, this can cause serious side
effects.
5. Conclusion
In summary, this study shows that intracerebroventricular
transplanted hUC-MSC partially prevent the spinal MNs loss and this ef-
fect is probably linked to the activation by IGF-1 of the p-Akt survival
pathway in both MN and in protective reactive astrocytes. This study
further strengthens the hypothesis that the protective effect of hUC-
Fig. 6.Evaluation of pro- and anti-inflammatory cytokines and IGF-1. Real-time PCR reveals thatmRNA levels of pro-inflammatory cytokines IL-6 (A) and IL-1β (B) tended to inhUC-MSCs-
treatedmice compared to the group treatedwith PBS (*= p b 0.05 vsNTG).mRNA levels of pro-inflammatory cytokine IL-4 (C) strongly increased in hUC-MSCs-treatedmice compared to
the group treated with PBS (*p b 0.001 vs NTG; § = p b 0.001 vs SOD1G93A PBS) and IL-10 (D) decreased in PBS-treated mice compared to NTG, while in mice treated with hUC-MSCs
tended to increase (* = p b 0.05 vs NTG). Furthermore, mRNA levels of the IGF-1 strongly increased in hUC-MSCs-treated mice compared to the group treated with PBS (*p b 0.001 vs
NTG; § = p b 0.001 vs SOD1G93A PBS). Bar graphs are mean ± SEM as a percentage versus NTG controls (n= 4–5 animals for each group).
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tory (IL-6, IL-1β) to anti-inflammatory (IL-4, IL-10) and neuroprotective
(IGF-1) environment in the lumbar spinal cord. However, it also empha-
sizes that the protection of the motor neuron perikarya in the spinal
cord is not a condition sufficient to prevent the muscle denervation
and thereby to delay the disease progression. This agreeswith emerging
findings that the preservation and the maintenance of functional pe-
ripheral nervous system through its interaction with immune response
is essential for delaying disease progression in SOD1G93Amousemodel
and potentially to ALS patients. Thus, an integrated approach which
combines a neuroprotective treatment with the preservation of the pe-
ripheral motor axons and NMJs should increase the efficacy of ALS
therapy.Ethics approval
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Fig. 7.Activation of p-Akt pro-survival pathway. Panels A–I laser scanning confocalmicrophotographs of p-Akt (red, A, D, G) andGFAP (green signal in B, E, H) in the ventral horn of lumbar
spinal cord of SOD1G93Amice at symptomatic stage of the disease, compared to NTG littermates. In SOD1G93Amicewe observed that hypertrophic astrocyteswere co-stainedwith p-Akt
signal (arrow), that are in greater number in mice treated with hUC-MSCs. P-AKT immunoreactivity is also present in cells that, morphologically, we can recognize as motor neurons
(asterisks, B, E, H). Representative immunoblots performed on the lumbar spinal cord of transgenic mice treated with PBS or hUC-MSCs, at 140 days of age, and relative quantification.
There was a slight but significant increase of Akt phosphorylation (at Ser473) in mice treated with hUC-MSCs. Bar represents mean ± SEM (n = 4 animals per group). Data were
analyzed using One way ANOVA followed by post hoc Tukey test; * = p b 0.001 vs NTG; § = p b 0.01 vs SOD1G93A PBS.
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Fig. 8. Behavioral analysis and survival. The ICV treatmentwith hUC-MSCs showed no significant changes inweight loss (A) or improvement ofmotor performance in paw grip endurance
test (B) and in the Rota-Rod test (C) compared to SOD1G93Amice treatedwith PBS. The arrows are in correspondence of repeated treatments. Each point in the curves represents themean
± SEM (n= 14–15). Data were analyzed by Two Way ANOVA for repeated measures, followed by post-hoc Tukey's test. The treatment with stem cell showed no changes in survival
extension (D) compared to SOD1G93A mice treated with vehicle. The curve was evaluated by the Log-rank test, p= 0.8906; chisquare = 0.01891 (n= 12–15).
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